Identification and antifungal susceptibility patterns of Candida strains isolated from blood specimens in Iran

Archives of Clinical Infectious Diseases

Volumn 8, Issue 3, 2013, Pages

  Ghahri, Mohammad ^a   Mirhendi, Hossein ^b   Zomorodian, Kamiar ^c   Kondori, Nahid ^d  

^a IMAM HOSSEIN UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Candida parapsilosis; Fungemia; Polymerase chain reaction; Polymorphism; Restriction fragment length; Voriconazole

Indexed keywords

CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; VORICONAZOLE;

ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BACTERIAL STRAIN; BLOOD CULTURE; BLOOD SAMPLING; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CONTROLLED STUDY; DNA CLEAVAGE; FEMALE; FUNGAL STRAIN; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HUMAN; HUMAN CELL; IRAN; KLUYVEROMYCES MARXIANUS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 84898887954     PISSN: 23452641     EISSN: 20081081     Source Type: Journal    
DOI: 10.5812/archcid.14529     Document Type: Article

References (19)

1. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 2009;115(20):4745-52.
2. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37(9):1172-7.
3. Chen LY, Liao SY, Kuo SC, Chen SJ, Chen YY, Wang FD, et al. Changes in the incidence of candidaemia during 2000-2008 in a tertiary medical centre in northern Taiwan. J Hosp Infect. 2011;78(1):50-3.
4. Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis. 1999;29(2):253-8.
5. Zirkel J, Klinker H, Kuhn A, Abele-Horn M, Tappe D, Turnwald D, et al. Epidemiology of Candida blood stream infections in patients with hematological malignancies or solid tumors. Med Mycol. 2012;50(1):50-5.
6. Cohen Y, Karoubi P, Adrie C, Gauzit R, Marsepoil T, Zarka D, et al. Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients. Crit Care Med. 2010;38(3):826-30.
7. Metin DY, Hilmioglu-Polat S, Samlioglu P, Doganay-Oflazoglu B, Inci R, Tumbay E. Evaluation of antifungal susceptibility testing with microdilution and Etest methods of Candida blood isolates. Mycopathologia. 2011;172(3):187-99.
8. Amran F, Aziz MN, Ibrahim HM, Atiqah NH, Parameswari S, Hafiza MR, et al. In vitro antifungal susceptibilities of Candida isolates from patients with invasive candidiasis in Kuala Lumpur Hospital, Malaysia. J Med Microbiol. 2011;60(Pt 9):1312-6.
9. Lewis RE. Overview of the changing epidemiology of candidemia. Curr Med Res Opin. 2009;25(7):1732-40.
10. Mirhendi H, Bruun B, Schonheyder HC, Christensen JJ, Fuursted K, Gahrn-Hansen B, et al. Differentiation of Candida glabrata, C. nivariensis and C. bracarensis based on fragment length polymorphism of ITS1 and ITS2 and restriction fragment length polymorphism of ITS and D1/D2 regions in rDNA. Eur J Clin Microbiol Infect Dis. 2011;30(11):1409-16.
11. Rex JH, Alexsander BD, Andes D, Arthington-Skaggs B, Brown SD, Chaturvedi V, et al. Reference method for broth dilution antifungal susceptibility testing of yeasts. Clinical and Laboratory Standards Institute. 2008;28(14).
12. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008;112(11):2493-9.
13. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48(12):1695-703.
14. Playford EG, Marriott D, Nguyen Q, Chen S, Ellis D, Slavin M, et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med. 2008;36(7):2034-9.
15. Trofa D, Gacser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev. 2008;21(4):606-25.
16. Das I, Nightingale P, Patel M, Jumaa P. Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK. Int J Infect Dis. 2011;15(11):e759-63.
17. Arslankoylu AE, Kuyucu N, Yilmaz BS, Erdogan S. Symptomatic and asymptomatic candidiasis in a pediatric intensive care unit. Ital J Pediatr. 2011;37:56.
18. Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis. 2005;41(7):975-81.
19. Labbe AC, Pepin J, Patino C, Castonguay S, Restieri C, Laverdiere M. A single-centre 10-year experience with Candida bloodstream infections. Can J Infect Dis Med Microbiol. 2009;20(2):45-50.